Should screening for DPD deficiency be mandatory before 5-FU exposure?
Lim
Wan-Teck
WT
McLeod
Howard L
HL
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D054067:Dihydropyrimidine Dehydrogenase Deficiency; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000032:analysis / Q000235:genetics; D005472:Fluorouracil / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D008403:Mass Screening / Q000379:methods; D008659:Metabolic Diseases / Q000150:complications / Q000175:diagnosis* / Q000201:enzymology* / Q000235:genetics; D009102:Multiple Organ Failure / Q000139:chemically induced*; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D018579:Patient Selection; D010818:Practice Patterns, Physicians'; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D042943:Dihydrouracil Dehydrogenase (NADP); D005472:Fluorouracil